PD-L1-IN-5_product_DataBase

Bioactivity	PD-L1-IN-5 (X22) is an orally active PD-L1 inhibitor, with the IC50 value of 785.6 nM. PD-L1-IN-5 has anti-tumor activity in vivo[1].
Invitro	PD-L1-IN-5 (X22) (0-150 μM, 12 h) 在体外对 MC38 和 CT26 细胞没有明显的细胞毒作用[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> PD-L1-IN-5 相关抗体:
In Vivo	PD-L1-IN-5 (X22) (5 or 25 mg/kg , 每天口服持续20天) 通过上调肿瘤浸润和 CD8+ T 细胞的部分毒性，在 MC38 和 CT26 结肠癌的小鼠模型中表现出明显的抗肿瘤效果，但在免疫缺陷裸鼠同基因 CT26 结直肠癌模型中表现出较低的抗肿瘤作用，表明其抗肿瘤机制依赖于免疫系统[1]。SD 大鼠和 C57blo/6小鼠中的药代动力学分析[1]Animal model
CAS	2597056-85-2
Formula	C40H44ClFN4O8
Molar Mass	763.25
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Liu L, et al. Discovery of Novel PD-L1 Small-Molecular Inhibitors with Potent In Vivo Anti-tumor Immune Activity. J Med Chem. 2024 Mar 28;67(6):4977-4997.

PeptideDB